Isomorphic Labs announces first external financing
Isomorphic Labs →Isomorphic Labs announced its first external funding round, reporting [figure hidden] in financing led by Thrive Capital with GV participation and follow-on capital from Alphabet. The company said it would use the funding to develop its AI drug-design engine, advance its internal therapeutic pipeline and expand its team. The announcement described partnered programs with Eli Lilly and Novartis alongside internal programs focused primarily on oncology and immunology. It also highlighted AlphaFold 3, developed with Google DeepMind and released in May 2024. These are financing disclosures for the Isomorphic Labs business; the release does not specify individual investor allocations or assign the proceeds to the UK subsidiary.